Skip to main content

Table 1 Summary of patients and clinical responses

From: Human induced-T-to-natural killer cells have potent anti-tumour activities

Patient

Gender

Age

Histology

HLA-I scores

NCR ligands scores

% of ITNK cytotoxicity against K562

Route of administration

Date of infusion

Dose level

Doses (× 106/kg)

Toxicity

Responses

Response duration (Months)

GD001

M

47

NPC

2

5

61.5

I.V.

2019/04/19

1

2.26

None

Progress

NR

2019/04/23

1

2.26

2019/04/29

1

2.54

GD002

F

49

CRC

1

7

77.3

I.V.

2019/05/13

1

2.64

Slight fever, fatigue

Partial remissions

16

2019/05/27

2

7.04

2019/06/27

2

5.28

2019/07/20

3

10.57

2019/08/16

3

8.61

2019/09/20

1

2.36

2019/10/9

2

3.46

2019/12/03

2

4.38

2020/01/07

3

12.12

2020/04/15

3

11.53

2020/06/03

3

9.56

2020/07/14

3

9.48

2020/08/19

3

9.48

2020/09/22

2

5.53

GD003

M

42

Rhabdomyosarcoma

3

3

51.0

I.A. a

2019/08/02

1

4.00

Slight fever, fatigue, muscle pain

Progress

NR

2019/08/16

0

0.15

2019/08/29

1

1.33

GD004

M

29

Melanoma

1

7

71.3

I.A.

2019/08/16

1

1.26

Slight fever, fatigue

Stable

1

GD005

F

61

Gastric cancer

1

7

75..9

I.V.

2019/08/28

0

0.31

None

Stable

1

GD006

F

28

AMC

1

6

74.0

I.A. b

2019/06/09

1

1.09

None

Stable

3

I.V.

2019/08/11

2

4.42

GD007

M

63

NSCLC

NA

NA

91.1

I.V.

2019/10/24

1

3.32

Slight fever, fatigue

Stable

3

GD008

M

59

CRC

NA

NA

83.1

I.T. c

2020/03/04

1

2.51

Slight fever, fatigue

Stable

1.5

I.V.

2020/03/09

1

2.51

GD009

M

68

Melanoma

NA

NA

15.1

I.V.

2019/08/27

1

2.37

Slight fever

Progress

NR

I.V.

2019/10/01

2

3.36

  1. I.V intravenous, I.A.a Hepatic arterial and ascending aortic injection, I.A.b uterine artery injection, I.T.c intra-tumour injected, Information of the seven patients in the ITNK clinical trial on gender, age, cancer type, HLA-I and NCR ligands expression in tumour biopsy, ITNK cytotoxicity, ITNK infusion dosage, toxicity, clinical outcomes and response duration. NPC nasopharyngeal carcinoma, CRC colorectal cancer, AMC appendices mucinous cystadenocarcinoma, NSCLC non-small cell lung carcinoma, NA not available, NR no response